Q-omics provides the consensus-scored TMEM154 profile across patient tissues and cancer cell-line models. TMEM154 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM154 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TMEM154 RNA expression shows 18,672 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where TMEM154 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM154 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM154 survival associations across molecular data types. TMEM154 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM154 RNA expression–survival associations across cancer types. High TMEM154 expression shows unfavorable associations in UVM, LGG, MESO and PAAD, but favorable associations in THCA and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM154 RNA expression.
This table summarizes TMEM154 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM154. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM154 shows lower tumor expression in KICH and LIHC and higher tumor expression in THCA, COAD, LUSC and BRCA. The THCA box plot shows higher TMEM154 RNA expression in tumor versus normal tissue (log2 FC = +1.252, t-test p < 0.001).
This table shows molecular features associated with TMEM154 in patient tissues and cancer cell lines. In patient samples, TMEM154 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM154 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
